Observational study of inclisiran effectiveness in Moscow healthcare

Observational study of inclisiran effectiveness in Moscow healthcare

Aim. To evaluate the effectiveness of PCSK9 inhibitors (alirocumab, inclisiran and evolocumab) in patients with atherosclerotic cardiovascular disease (ASCVD) and failure to achieve the target low-density lipoprotein cholesterol (LDL-C) level for the period from November 21, 2022 to December 31, 202...

Full description

Saved in:

Bibliographic Details
Main Authors:	A. I. Sapina, Yu. Yu. Varlamova, M. G. Papyrina, A. S. Bezymyannyy, E. Yu. Vasilyeva
Format:	Article
Language:	Russian
Published:	«FIRMA «SILICEA» LLC 2023-12-01
Series:	Российский кардиологический журнал
Subjects:	atherosclerosis inclisiran pcsk9 inhibitors
Online Access:	https://russjcardiol.elpub.ru/jour/article/view/5687
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Effectiveness of inclisiran lipid-lowering therapy in patients with atherosclerotic cardiovascular disease in Moscow healthcare
by: A. I. Sapina, et al.
Published: (2024-06-01)

Efficacy and safety of inclisiran versus PCSK9 inhibitor versus statin plus ezetimibe therapy in hyperlipidemia: a systematic review and network meta-analysis
by: Shengxuan Zhang, et al.
Published: (2024-11-01)

Prospects of Using PCSK9 Inhibitors for Acute Coronary Syndrome
by: A. M. Namitokov, et al.
Published: (2024-04-01)

Evaluation of lipoprotein(a) — a novel cardiovascular risk factor in patients with atherosclerotic cardiovascular diseases receiving PCSK9-targeted therapy in Russian real-world practice
by: A. I. Sapina, et al.
Published: (2025-01-01)

New opportunities for lowering low-density lipoprotein cholesterol: comparative characteristics of PCSK9-targeted therapy
by: S. K. Zyryanov, et al.
Published: (2022-12-01)

PCSK9 Inhibitors: Focus on Evolocumab and Its Impact on Atherosclerosis Progression
by: Maram H. Abduljabbar
Published: (2024-11-01)

Effect of atorvastatin and rosuvastatin on the PCSK9 blood concentration in statin-naive patients with atherosclerosis
by: A. Yu. Filatova, et al.
Published: (2019-06-01)

Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) to tackle central nervous system diseases: role as a promising approach
by: Xiaoxiao Zheng, et al.
Published: (2025-07-01)

Atherosclerosis and inflammation – the path from pathogenesis to treatment: review of the current state of the issue (part 2)
by: A. A. Avagimyan, et al.
Published: (2025-07-01)

Relationship of sortilin and proprotein convertase subtilisin/kexin type 9 in blood serum with the severity of carotid and coronary atherosclerosis in hypertensive patients
by: Yu. Yu. Vukolova, et al.
Published: (2022-06-01)

Safety and Efficacy of Inclisiran in Hyperlipidemia: An Updated Meta‐Analysis of Randomised Controlled Trials
by: Jawad Basit, et al.
Published: (2025-03-01)

PCSK9-antibodies fail to block PCSK9-induced inflammation in macrophages and cannot recapitulate protective effects of PCSK9-deficiency in experimental myocardial infarction
by: Simon Rauterberg, et al.
Published: (2025-01-01)

Modulation of atherogenesis biomarkers by PCSK9 inhibitors in Lp(a)-stimulated human coronary artery endothelial cells
by: Rahayu Zulkapli, et al.
Published: (2025-07-01)

Inclisiran for the treatment of hypercholesterolaemia
by: Joel C Marrs, et al.
Published: (2024-11-01)

Value of proprotein convertase subtilisin/kexin type 9 and inflammatory markers in the diagnosis of carotid atherosclerosis in hypertensive men
by: Yu. Yu. Vukolova, et al.
Published: (2024-10-01)

Systemic evaluation of inclisiran on the risk of new-onset diabetes and hyperglycemia compared to evolocumab and atorvastatin
by: Fei Li, et al.
Published: (2025-07-01)

Carotenoid Interactions with PCSK9: Exploring Novel Cholesterol-Lowering Strategies
by: Alessandro Medoro, et al.
Published: (2024-11-01)

PCSK9 in T-cell function and the immune response
by: Yuying Wang, et al.
Published: (2024-12-01)

Innovative lipid-lowering therapy: experience of inclisiran use in the Republic of Belarus
by: E. A. Medvedeva, et al.
Published: (2023-05-01)

Analysis of The Use of PCSK9 Inhibitors in Clinical Practice
by: S. Yu. Volkova, et al.
Published: (2023-03-01)

Enfermedad cardiovascular: la necesidad de medidas urgentes
by: Luz C. Zárate-Correa, et al.
Published: (2025-01-01)

Immunotherapy and vaccine-based approaches for atherosclerosis prevention: a systematic review study
by: Mansoureh Shekarchizadeh Esfahani, et al.
Published: (2025-03-01)

Inhibitors in the Management of Patients with Atherosclerotic Cardiovascular Diseases: Guidelines and Reimbursement Issues
by: M. V. Zhuravleva, et al.
Published: (2020-09-01)

PCSK9 inhibitors – new era of dyslipidemia treatment - effectiveness in reducing low-density lipoprotein (LDL-C) and cardiovascular risk
by: Radosław Szydłowski, et al.
Published: (2024-12-01)

Past, Present, and Future of Familial Hypercholesterolemia Management
by: Viviane Z. Rocha, et al.
Published: (2021-09-01)

The Effects of Inclisiran on the Subclinical Inflammatory Markers of Atherosclerotic Cardiovascular Disease in Patients at High Cardiovascular Risk
by: Mateusz Maligłówka, et al.
Published: (2025-06-01)

PCSK9 inhibitors for in-hospital treatment of patients with acute coronary syndrome and severe lipid metabolism disorders
by: O. L. Barbarash, et al.
Published: (2020-09-01)

Triple Non-Statin Therapy with Ezetimibe, Inclisiran, and Bempedoic Acid in Patients with Genetically Confirmed Statin-Induced Rhabdomyolysis: A Dual Case Report
by: Jozef Dodulík, et al.
Published: (2025-05-01)

Alirocumab Administration Experience to Achieve Low Density Lipoprotein Cholesterol Target Levels in Secondary Prevention of Cardiovascular Disease
by: A. E. Nikitin, et al.
Published: (2020-03-01)

Features of lipid-lowering therapy in liver transplant recipients
by: A. A. Kucherov, et al.
Published: (2023-12-01)

New possibilities for lipid level control using inclisiran — prospects for interaction between a cardiologist and a neurologist
by: A. B. Skiba, et al.
Published: (2023-12-01)

PCSK9 Antagonists: Clinical Efficacy and Main Trends in the Development of New Medicines
by: A. A. Nekipelova, et al.
Published: (2023-09-01)

Cost-effectiveness analysis of using atorvastatin, simvastatin, ezetimibe, alirocumab, evolocumab, inclisiran in adults with very high cardiovascular risk under the preferential drug provision program
by: T. O. Bessonova, et al.
Published: (2023-04-01)

Mechanisms of action and therapeutic potential of PCSK9-regulating drugs
by: Chenrui Qi, et al.
Published: (2025-12-01)

Lower body mass index is associated with the achievement of target LDL in patients using PCSK9 inhibitors in Taiwan
by: Kuan-Chieh Tu, et al.
Published: (2025-03-01)

Gain of function variants in PCSK9 gene in high risk patients after myocardial infarction with increased lipoprotein (a) values and treated with statins
by: Sabina Ugovšek, et al.
Published: (2025-07-01)

HIGH INTENSITY HYPOLIPIDEMIC THERAPY AND DECREASED LEVEL OF LOW DENSITY LIPOPROTEIDES CHOLESTEROL: IS THE APPROACH JUSTIFIED? POINT OF VIEW
by: M. G. Bubnova
Published: (2018-07-01)

Lipoprotein(a): Assessing the Current Knowledge and Gaps in Screening and Treatment—A Narrative Review
by: Octavian Amaritei, et al.
Published: (2025-04-01)

Indirect comparison of the efficacy and safety of alirocumab and evolocumab on major cardiovascular events: a systematic review and network meta-analysis
by: Leyu Xu, et al.
Published: (2025-06-01)

PCSK9 inhibitors reduces arterial stiffness in patients with acute coronary syndrome
by: Wang Liang, et al.
Published: (2025-01-01)